Biotech News & Trading Forum: Community User: Weedmaster

😁😁😁

Schorsch Celsion 🚀🌶

https://www.nytimes.com/2021/02/09/health/universal-coronavirus-vaccine.html

ASRT ITRM Beide mit Offering heute und Gelegenheit zum Einstieg.

Vistagen heute günstig zum einsammeln

Fresenius Medical FSM interessant als Rebound Kandidat, aktuell sehr nahe am Jahrestief

👍

Bin froh, bei 0.21 rein zu sein moma 😅

Intellipharma Schorsch 😀

Ja, läuft.😁😁 KMPH mit PDUFA-Run TNXP OGEN LIFE ADXS auch

Zumindest vorbörslich. 😁

Schorsch, Celsion 🚀

ProQR Therapeutics PRQR 50m Aktien  $250m MC $74m Cash $3m burn/Monat  Ph 2/3 Illuminate trial completed enrollment January 2021, top-line data expected H1 2022 Pediatric trial expected to start 2021 1/2 InSight extension study to be reported in H2 2021 Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim analysis expected in H1 2021 Initial data from Phase 1/2 trial of QR-1123 expected in 2021 QR-504a clinical study in Fuchs expected to start in H1 2021 Cash runway into 2023 Patent terms (excluding potential extensions): • sepofarsen for LCA10 through 2036 • QR-421a for Usher exon 13 through 2037 • QR-1123 for adRetinitis Pigmentosa through 2036 • QR-504a for Fuchs Endothelial Corneal Distrophy through 2036 • QR-411 for Usher PE40 through 2037 • QR-1011 for Stargardt disease through 2038 • Axiomer® platform technology through 2041 https://www.proqr.com/files/2021-01/ProQR-Corporate-Presentation_0.pdf

Remaining February/March PDUFA and Advisory Committee dates: https://www.biopharmcatalyst.com/news/2021/week-two-biotech-earnings-preview-biotech-week-in-review